Printer Friendly

CAMBRIDGE NEUROSCIENCE, INC. APPOINTS FORMER CIBA-GEIGY CLINICAL RESEARCH DIRECTOR AS VICE PRESIDENT, CLINICAL STUDIES

 CAMBRIDGE, Mass., July 22 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) today announced the appointment of Heikki Hakkarainen, M.D., to the newly created position of vice president, Clinical Development. For the past 13 years Dr. Hakkarainen has been responsible for the development of central nervous system products and neuroprotective agents for CIBA-GEIGY, serving most recently as International Project Leader, Neuroprotective Agents, CIBA-GEIGY Corporation.
 "Dr. Hakkarainen's arrival is particularly timely given the accelerated clinical development of our lead compound Cerestat(tm), and the expansion of clinical trials of the drug for both stroke and traumatic brain injury patients," said Elkan Gamzu, Ph.D., president and chief operating officer. "Dr. Hakkarainen has tremendous experience in designing and supervising U.S. and international clinical research programs, and regulatory submission, for neuroprotective agents in stroke and head trauma."
 Dr. Hakkarainen joined CIBA-GEIGY in 1980 as a project leader, and later became deputy section leader, for the company's CNS Medical Department in Basel, Switzerland. In 1986, he was named executive director of CIBA-GEIGY's CNS Clinical Research in New Jersey, responsible for planning, implementing and managing the company's clinical research studies for more than 20 products, and the clinical sections of two successful New Drug Applications. He was promoted to International Project Leader, Neuroprotective Agents, in 1990.
 After receiving his M.D. from the University of Turku, Finland, Dr. Hakkarainen began his career as an academic neurologist, eventually becoming chief of Neurology at University Hospital, Tampere, Finland. He received resident training at the University of Oulu, Finland, where he also served as associate professor of Neurology. Dr. Hakkarainen has published more than 65 scientific papers or abstracts in the field, and is fluent in English, German, Swedish and Finnish.
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceuticals with a focus on nerve cell survival. The company is developing a number of products to treat stroke, traumatic brain injury, schizophrenia and chronic neurodegenerative disorders such as diabetic peripheral neuropathy and multiple sclerosis.
 -0- 7/22/93
 /CONTACT: Philip V. Holberton, vice president and CFO, Cambridge NeuroScience, Inc., 617-225-0600, ext. 106; Marcia A. Kean, executive vice president, or Chris Taylor, account executive, Feinstein Partners Inc., 617-577-8110, for Cambridge NeuroScience/
 (CNSI)


CO: Cambridge NeuroScience ST: Massachusetts IN: MTC SU: PER

DJ -- NE004 -- 4434 07/22/93 10:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1993
Words:388
Previous Article:THE KENDALL COMPANY REPORTS SECOND QUARTER RESULTS
Next Article:TEXACO RESULTS FOR THE SECOND QUARTER AND FIRST HALF 1993
Topics:


Related Articles
CIBA-GEIGY EXECUTIVE JOINS GENE THERAPY COMPANY, TRANSKARYOTIC THERAPIES
Cambridge NeuroScience Inc. Appoints Director, Marketing to Initiate Marketing Plan for Cerestat(R)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters